As of September 30, 2026, HOFSETH BIOCARE AS has 506.23M shares outstanding.
| Shares Outstanding | 506.23M |
As of September 30, 2026, HOFSETH BIOCARE AS maintains a current ratio of 0.96, meaning it holds 1.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -11,441.34, indicating conservative leverage, while an interest coverage ratio of -1.40 demonstrates limited ability to service its debt obligations.
| Current Ratio | 0.96 |
| Quick Ratio | 0.22 |
| Debt / Equity | -11,441.34 |
| Debt / EBITDA | -5.89 |
| Interest Coverage | -1.40 |
These figures cover the twelve months ended September 30, 2026. Return on assets (ROA) is negative at -32.25, reflecting losses generated across the asset base. The company generates approximately 335,535.52 in revenue per employee across its workforce of 84.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.32 indicates how many times HOFSETH BIOCARE AS sells and replaces its inventory over a year, a key working capital efficiency ratio.
| Return on Assets (ROA) | -32.25 |
| Revenue Per Employee | 335,535.52 |
| Employee Count | 84.00 |
| Inventory Turnover | 2.32 |
Over the twelve months ended September 30, 2026, HOFSETH BIOCARE AS recorded 18,943.83 in income tax expense. The company reported a pretax loss of -12.59M and -12.61M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.
| Income Tax | 18,943.83 |
As of the close on October 26, 2026, HOFSETH BIOCARE AS's stock has declined approximately 28.99% over the past 52 weeks.
| 52-Week Price Change | -28.99% |
| 50-Day Moving Average | 0.71 |
Over the twelve months ended September 30, 2026, HOFSETH BIOCARE AS generated 28.18M in revenue and converted that into -12.61M in net income, yielding earnings per share of -0.03. EBITDA reached -4.99M, while operating income came in at -9.32M.
| Revenue | 28.18M |
| Gross Profit | 12.26M |
| Operating Income | -9.32M |
| Pretax Income | -12.59M |
| Net Income | -12.61M |
| EBITDA | -4.99M |
| EBIT | -9.32M |
| Earnings Per Share (EPS) | -0.03 |
As of September 30, 2026, HOFSETH BIOCARE AS holds 3.50M in cash and equivalents against 29.36M in total debt, resulting in a net debt position of 18.11M. Total book value stands at -184,754.38, with working capital of -709,456.82 providing operational flexibility.
| Cash & Cash Equivalents | 3.50M |
| Total Debt | 29.36M |
| Net Debt | 18.11M |
| Equity (Book Value) | -184,754.38 |
| Working Capital | -709,456.82 |
HOFSETH BIOCARE AS produced -4.37M in operating cash flow over the twelve months ended September 30, 2026. After subtracting -3.16M in capital expenditures, free cash flow totaled -7.52M - equivalent to -0.02 per share.
| Operating Cash Flow | -4.37M |
| Capital Expenditures | -3.16M |
| Free Cash Flow | -7.52M |
| FCF Per Share | -0.02 |
Over the twelve months ended September 30, 2026, HOFSETH BIOCARE AS posted a gross margin of 43.50, reflecting its pricing power and cost economics. The operating margin of -33.07 and net profit margin of -44.73 provide insight into operational efficiency.
| Gross Margin | 43.50 |
| Operating Margin | -33.07 |
| Pretax Margin | -44.66 |
| Profit Margin | -44.73 |
| EBITDA Margin | -17.69 |
HOFSETH BIOCARE AS's most recent stock split took place on October 16, 2020.
| Last Split Date | 10/16/2020 |
Already premium?